After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
The graduating cohort comprised seven batches across five specialized programs
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
The company highlighted continued demand strength and pricing resilience despite global disruptions
More than 450 public and private health technology solutions have integrated with the Ayushman Bharat Digital Mission ecosystem
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
